Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria

Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria

Medicines for Malaria Venture and the Africa CDC sign Memorandum of Understanding to support African manufacturers

Strong recommendation for pyronaridine-artesunate in revised WHO Malaria Treatment Guidelines

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria

First African-manufactured medicine to prevent malaria in pregnant women and infants quality-approved by WHO

MMV and IVCC make 240 compounds available to stimulate research into new drugs and insecticides

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria

New partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa

This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria

New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

MMV supports the launch of the new Fight the Fakes Alliance

Largest clinical trial in Africa to treat COVID-19 cases before they become severe

GSK and MMV present positive data on treatment of Plasmodium vivax malaria

Endemic countries in South America meet to discuss new tools for malaria elimination

Global call to boost access to lifesaving malaria treatment for pregnant women in Africa

MMV launches the COVID Box to stimulate new drug research

This World Malaria Day MMV supports Swiss Malaria Group's call for urgent action

Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria

MMV and LSTM collaborate to fill data gap on use of antimalarials during pregnancy

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa